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Summary
Highly active antiretroviral therapy (HAART) has proved efficient in increasing CD4 counts in 
many randomized clinical trials. Because randomized trials have some limitations (e.g., short 
duration, highly selected subjects), it is interesting to assess the effect of treatments using 
observational studies. This is challenging because treatment is started preferentially in subjects 
with severe conditions. This general problem had been treated using Marginal Structural Models 
(MSM) relying on the counterfactual formulation. Another approach to causality is based on 
dynamical models. We present three discrete-time dynamic models based on linear increments 
models (LIM): the first one based on one difference equation for CD4 counts, the second with an 
equilibrium point, and the third based on a system of two difference equations, which allows 
jointly modeling CD4 counts and viral load. We also consider continuous-time models based on 
ordinary differential equations with non-linear mixed effects (ODE-NLME). These mechanistic 
models allow incorporating biological knowledge when available, which leads to increased 
statistical evidence for detecting treatment effect. Because inference in ODE-NLME is 
numerically challenging and requires specific methods and softwares, LIM are a valuable 
intermediary option in terms of consistency, precision and complexity. We compare the different 
approaches in simulation and in illustration on the ANRS CO3 Aquitaine Cohort and the Swiss 
HIV Cohort Study.
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1. Introduction
Randomized clinical trials often have short durations and include highly selected subjects, 
thus assessing the effect of a treatment using observational studies is useful. However, it is 
challenging because the treatment may change, and covariate history of a subject up to time t 
may influence treatment given after t, and may also influence the outcome of interest, which 
induces a time-dependent confounding. For instance, one may wish to assess the effect of 
antiretroviral therapy in HIV infected subjects. As CD4+ T-lymphocytes (CD4, in short) are 
the main target cells of the HIV virus, it is possible to assess the effect of a treatment on the 
blood concentration of these cells: CD4 counts are measurements of this concentration. In 
observational studies, however, the decision to start an antiretroviral therapy may depend on 
CD4 counts as well as on other covariates. In this setting, it has been demonstrated that a 
conventional regression analysis leads to biased estimates of the treatment effect, typically 
underestimating it, and possibly (wrongly) indicating a negative effect. This is called 
“confounding by indication” (Walker, 1996).
Marginal structural models (MSM) (Robins et al., 2000) have been proposed for dealing 
with this issue; this is based on choosing a causal model in terms of potential responses, 
which are often counterfactual, to the different treatment histories. The parameters of a 
MSM can be estimated through a weighted approach but other methods exist (Petersen et al., 
2006). The weights are the inverse probability of treatment assignment and are obtained 
through a “treatment model” which includes the covariates linked to the outcome. Because 
data are correlated, we use an inverse probability weighted generalized estimating equation 
(GEE). This approach has been applied by Hernán et al. (2002) and Cole et al. (2005) for 
estimating the effect of zidovudine and of highly active antiretroviral therapy (HAART) on 
CD4 count.Cole et al. (2007) and Sterne et al. (2005) used it for estimating the effect of 
HAART on viral load and on AIDS or death.
An alternative view to causality, that does not use the potential responses representation is to 
use dynamic models. This has been pioneered by Granger (1969); Dawid (2000), and further 
developed by Didelez (2008), Commenges and Gégout-Petit (2009), Gégout-Petit and 
Commenges (2010) and Eichler and Didelez (2010). Assumptions needed for a causal 
interpretation of dynamic models have been presented in Arjas and Parner (2004) and 
Commenges and Gégout-Petit (2015). Dynamical models in discrete time, and in particular 
linear increment models (LIM), have been proposed by Diggle et al. (2007) and Ho et al. 
(2014). Aalen et al. (2012) have suggested that such models can be useful for studying the 
HAART effect on CD4 counts or viral load. Discrete-time models, however, may not be 
completely satisfactory because the processes of interest most often exist in continuous time. 
Systems of differential equations in continuous time can also be used to model the 
interaction between HIV and CD4 cells populations. Models based on differential equations, 
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called “mechanistic”, considerably helped in understanding some important features of the 
infection: see Perelson (2002) for a review. In our setting, it is possible to model the 
treatment effect from a biological perspective. Introducing random effects is an efficient way 
to model differences between subjects with a minimum of additional parameters (Wu, 2005; 
Guedj et al., 2007; Lavielle et al., 2011). Mechanistic models have mostly been used to 
analyze data from clinical trials. Using mechanistic models to estimate the effect of HAART 
based on data of large observational cohorts is possible, but to our knowledge, has never 
been attempted.
The aim of this paper is to propose dynamic models in discrete and continuous time for 
assessing the causal effect of a treatment on a marker in observational studies. Specifically, 
we aim to estimate the HAART effect in HIV infected patients. We present several possible 
dynamic models, as well as MSMs, and compare them using simulations and real data. 
Although we worked out analytics in simple cases (see Appendix), the comparison is mainly 
empirical and aims to describe the assumptions and variability of results provided by the 
various methods. In Section 2, we present the statistical models: the naive model, the MSMs, 
the discrete-time dynamic models and the mechanistic approach. In Section 3, we compare 
the results of these models in simulation, where the data are generated from a complex 
mechanistic model. Section 4 is the application on the data of two cohorts of HIV infected 
patients: the Swiss HIV Cohort Study (SHCS) and the ANRS CO3 Aquitaine cohort. 
Section 5 concludes.
2. Modeling the treatment effect in observational studies
2.1 Notations and the naive model
We denote the value of a physiological marker for subject i at time t by , say the CD4 
count. The value of a treatment given at time t to subject i is denoted by , say HAART. For 
sake of simplicity, we only model two treatment states:  when treatment is not given, 
and  when treatment is given, and we assume that once initiated the treatment is not 
interrupted; however, one could expand the model to accommodate different levels of 
treatment. If treatment is started at time t then  and . We use overbars to 
represent the histories of these processes: for instance . We denote by 
 the cumulative time under treatment until time t. In the absence of 
confounding by indication, the simplest model would be to regress  on . Cole 
et al. (2005) notes the advantages of a piecewise linear regression model that allows a 
change in the effect of treatment after one year. Thus, our Model 1 is a naive model with 
different treatment effects before and after one year:
(2.1)
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where  is the cumulative time under treatment up to time t minus one year: 
(with the convention  for t < 0). The β’s 
can be estimated by conventional GEE (Liang and Zeger, 1986) because we are interested in 
the population average. We use the independence working correlation structure in our 
analyses; otherwise results could be biased because of the presence of time-varying 
covariates (Pepe and Anderson, 1994).
2.2 Marginal structural models (MSM)
Because treatment is given to subjects with low CD4 counts, treated subjects tend to have 
low CD4 counts. Thus, the true value of parameter β1 in Model 1 cannot be interpreted as 
the causal effect. MSMs are designed to estimate the causal effect of a treatment given time 
dependent confounding. It is assumed that to each particular value of treatment history  of 
, a potential outcome  is associated (possibly contrary to the treatment actually 
received). A model is postulated to describe how the potential outcomes vary as a function 
of the different treatment trajectories. Hernán et al. (2002) and Cole et al. (2005) proposed 
benchmark models that also adjust for confounders such as time (t) and baseline value of 
biomarkers (Y0) in the regression. To duplicate this, our Model 2 is::
(2.2)
Robins et al. (2000) showed that the causal parameters of this model can be estimated with a 
suitably weighted GEE. The weights represent the inverse probability of treatment. The 
probability of treatment at time t depends on the history up to time t of a vector of variables 
L denoted  typically includes include . The probability of treatment 
is estimated at each point in time using a treatment model (generally a logistic model) and 
the weights are the product over time of these probabilities; one often use stabilized weights 
as in Equation 2.3. An extension allows for censoring (Cole et al., 2005; Cole and Hernán,
2008), however, the most important correction is generally for the probability of treatment 
(Ko et al., 2003). Stabilized inverse probability of treatment weights are defined as:
(2.3)
Results from Model 2 are consistent if the treatment model corresponds to the true treatment 
assignment mechanism; i.e. if all the confounders (factors influencing both the outcome of 
interest and treatment assignment) have been taken into account. We defined L for treatment 
model in Model 2 as baseline and time-varying CD4 count in categories (< 200, [200; 400], 
> 400), viral load in categories (< 401, 401 – 10000 and > 10000), and an indicator of 
undetectable viral load. In Models 1 and 2 the effect of treatment on CD4 counts during the 
first year is given by β1 and the effect after one year of treatment is given by β1 + β2.
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2.3 Modeling the increment with a dynamical MSM
It is more relevant to model the change in the marker of interest, rather than its current value. 
This fits well with a causal thinking which considers that the change of a process depends on 
its present, and possibly past, states. Thus, we could model ; in order to account 
for non-equally spaced measurements, we might assume that the change in biomarker values 
is proportional to the time elapsed between two measurements; that is, , where 
 is the tth calendar time of observation since the baseline measure of subject i. We define 
the biomarkers increments as . We take this approach when developing linear 
increment models in Section 2.4. However it is possible to express a MSM for the ’s as:
(2.4)
Our Model 3 is then the combination of this MSM for  together with the treatment model 
(2.3). Note that with equally spaced measurements, Model 2 and 3 will be structurally 
identical if the same unit of time (e.g. year) is used for  and the cumulative exposures (see 
Appendix). Inference approaches will be different, thus, Model 3 should be more suitable 
than Model 2 because we use an independence working correlation matrix for the ’s, 
which is much more acceptable than assuming independence for the ’s.
2.4 Full discrete-time dynamical models - linear increment models (LIM)
We can also fit a linear mixed-effects model for the ’s. The inter-subject variability is 
accounted for by a random effect b assumed normally distributed with zero expectation. 
Thus, LIM specify the distribution of Zi conditional on the bi. We propose three LIM; the 
simplest is Model 4, where the ε’s are i.i.d. normal variables with zero expectation:
(2.5)
In both Models 3 and 4, the effect of treatment on the CD4 counts is  during the first 
year of treatment, and  after one year, where  is the mean of all the .
Many deterministic dynamical models have equilibrium points; similarly many stochastic 
dynamical models tend toward a stationary process. This property fits very well with the 
behavior of biological systems since concentrations of many molecules or cells have a 
tendency to return to the same value, a property called “homeostasis”. Difference equations 
of the type  correspond to an autoregressive model of order one, 
denoted AR(1):  with γ′ = (γ1 + 1). It is well known that if |γ′| < 1 this 
process converges toward a stationary process (in discrete time) with expectation 
; this is always defined unless γ1 = 0, as is the case in Model 4 
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which does not have a finite stationary expectation. When using a model which has this 
convergence property, it may not be necessary to have a two-slope model. For example, we 
define Model 5, which tends to a stationary process with expectation  for treated 
patients if −2 < β2 < 0 and β0 + β1 > 0:
(2.6)
A more realistic modeling of CD4 counts takes viral load into account. Here, we make a step 
toward mechanistic models because we know that the virus concentration and the CD4 
concentration are inter-related processes. Thus, Model 6 is based on a system of two 
difference equations:
(2.7)
where , with  the viral load at time t for patient i. The random effects 
di and bi, and the errors  and  are all i.i.d. and normally distributed with zero 
expectation. In Model 5 and 6, one year and subsequent years increase in CD4, as well as the 
long term change, are easily computed by solving the difference equations numerically. 
Moreover, for testing whether the treatment has an effect, it is convenient to test the 
hypotheses β1 = 0 and α1 = 0, by Wald tests for instance. As a reviewer notes, an interesting 
question is the correspondence between LIM and MSM. The Appendix shows that under 
some (rather strong) assumptions, Model 4 estimates the same causal parameters as Models 
2 and 3 without using a treatment model.
2.5 Continuous Dynamical models, Mechanistic Models (ODE-NLME)
In reality, biomarkers processes exist in continuous time. A natural extension of a dynamic 
model in discrete time, as , is a model based on differential equations. (Perelson, 
2002) give a review of some models for HIV dynamics based on ODE systems. In this 
article, we consider the “target cells model”, called Model 7 and described bellow, which 
proved to provide a good fit and prediction abilities (Prague et al., 2013).
Biological system—We know that only infected cells (T*) can produce viruses (V). The 
target cells model distinguishes between uninfected quiescent cells (Q) and target cells (T). 
The instantaneous change of concentrations of these populations at time t, for all real value 
of t > 0, is given by the ODE system:
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(2.8)
The system is graphically represented in Figure 1a. Here, the parameters have biological 
meanings: λ is the production rate of new CD4 cells, the μ’s are death rates of different 
populations of cells, α and ρ are transition rates between quiescent and target cells, π is the 
rate of production of virions by infected cells, and γ is the infectivity parameter. The model 
assumes that the rate of infection of target cells is γVt.
Inter-individual variability—A model that allows parameters to vary between individual 
is a mixed effects model. We model the inter-individual variability on the log-transformed 
parameters denoted with a tilde to ensure positiveness during estimation. In this application, 
two random effects  and  are introduced (Prague et al., 2012):  and 
. Biologically, the causal effect of treatment can be modeled as an effect on 
the infectivity parameter γ. The parameter γ depends on t through , where we expect β < 
0, so that the treatment decreases the infectivity of the virus:
(2.9)
Observation model—One important consequence of using continuous time models is that 
we must distinguish between the biological system which exists in continuous time and 
observations which are made at discrete times. To make an additive model for measurement 
error acceptable, we use 4th-root transformation for CD4 and a log10 transformation for the 
viral load. With errors  and  both i.i.d. and normally distributed, the observation model 
is:
(2.10)
Inference—Inference is much more complex and computationally demanding than in 
discrete-time models. We base inference on a penalized maximum likelihood approach and 
to achieve identifiability, we include prior knowledge of mechanistic parameters. Our priors 
(Table 1) are based on estimates in the literature of these parameters (Prague et al., 2012). 
This approach has been implemented in the NIMROD program (Prague et al., 2013). 
Assessing the long-term treatment effect in Model 7 is possible by analytically computing 
the equilibrium point. One year and subsequent year increase in CD4 after treatment 
initiation can be computed by solving the ODE system for given values of the random 
effects. The marginal effect can be computed as the mean of the individual effects in the 
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population. The β parameter in the infectivity definition gives the effect of treatment, and a 
Wald test can be used to test the no-effect hypothesis (β = 0).
3. Simulation study
We simulated data with the Adams et al. (2005) model made up of two populations of target 
cells and a population of immune effectors such as cytotoxic T-lymphocytes (see Figure 1b 
and Table 1), which is much more complex than Model 7 (see Web-Supplementary Material 
A4). Individual variability was introduced by drawing parameters from normal distributions 
(with mean values listed in Table 1 and variances chosen to obtain a variation coefficient of 
50%). By controlling the value of random effects, we ensured that the steady state baseline 
distributions of CD4 counts and viral load were consistent with the baseline values 
distributions found in Aquitaine cohort and SHCS dataset. See Web-supplementary Material 
A1 for details. We generated observations every 3 months; the standard deviations of the 
measurement errors were σVL = 0.6 and σCD4 = 0.1. Viral load was artificially made 
undetectable at the level of 50 copies/mL. Treatment assignment was done by simulating a 
CD4 count assessment at every observation and by fixing a probability of treatment 
assignment depending on the observed CD4 count. We took empirical probabilities from the 
Aquitaine cohort and SHCS dataset: treatment was attributed in 2%, 28% or 47% of patients 
where their CD4 count was > 400, [400, 200] or < 200. No other confounder was 
considered. Simulated patients are supposed fully observed for 5 years. We simulated n=200 
and n=1500 patients. Table 3 gives a general description of both simulated and real datasets 
and there is no obvious difference between simulated and real cohort data in their descriptive 
statistics. We define the “average causal effect in treated patients” as the mean difference 
between the observed CD4 according to the observed treatment initiation and the 
counterfactual CD4 under no treatment initiation. The result of this computation was a 350 
cells increase in CD4 after 1 year, a 362 cells increase after 2 years and an overall increase 
of 370 CD4 cells after an infinite (large) time. Technical details and code for analysis are 
described in Web-Supplementary Material C.
Table 2 presents the estimates for Models 1-7 on the simulated datasets. The naive Model 1 
largely underestimated the treatment effect. This was corrected by the MSM Models 2 and 3 
(see details about weights in Web-Supplementary Material A2). Model 4 also yielded good 
estimates of the mean causal effect in treated patients. Moreover, it led to an increased 
significance of results compared to Model 3 for increase in CD4 count during the first year. 
Regarding increase in CD4 count in subsequent years, whereas the Model 3 underestimate 
its variability (for large samples, 12 ∉ [2; 6]), Model 4 is more reliable (for large samples, 12 
∈ [−1; 15]). This underestimation of the variance of Model 3 may be driven by an overfitting 
of inverse probability of treatment weights. This overfitting could have arisen because the 
data generation was based on CD4 cell count evolution and not on viral load, whereas the 
inverse probability of treatment weights were calculated from treatment models with both 
past CD4 cell count and viral load as predictors. We note that long-term increase in CD4 is 
infinite in Models 1 to 4, even though it happens at a really slow rate. On the contrary, 
Models 5-7 exhibit an equilibrium point which makes it possible to consider the long-term 
causal effect of treatment. All dynamic models gave an estimate of the long-term effect of 
treatment for which the true value was included in the 95% confidence interval. The initial 
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increase in CD4 during the first year was not correctly reproduced by Model 5. Models 6 
and 7 which both incorporate the dynamics of viral load gave a better estimate of the 
increase in CD4 count (see details about estimated values of biological parameters in the 
Model 7 in Web-Supplementary Material A3). All models found a significant effect of 
treatment on CD4 counts in the first year. Sandwich estimators were used for calculating the 
standard errors for GEE methods and Fisher information matrix was used for methods based 
on maximum likelihood. Altogether, the dynamic models (Model 4-7) have greater statistical 
evidence, with higher Z-statistics rejecting the no-effect hypotheses, than the GEE based 
models (Models 1-3). Finally, while fitting Models 1-6 took less than a minute on a typical 
laptop, fitting Model 7 took about 10 hours of parallel computing with 100 cores. All results 
and conclusions are similar in small and large samples.
4. Real data
We used two large cohorts: the ANRS CO3 Aquitaine cohort (Thiébaut et al., 2000) and the 
Swiss HIV Cohort Study (SHCS) (Sterne et al., 2005; Gran et al., 2016). Like Cole et al. 
(2005), we took a sub-sample of patients who were alive, HIV positive, yet untreated and 
under follow-up in April 1996 when HAART became available. All patients taking only one 
or two antiretroviral drugs (rather than HAART) were excluded. Once a patient was on 
HAART, we assumed he or she remained on it. For each patient, follow-up began with the 
first visit after April 1996 and ended with 1) the last visit at which he or she was seen alive, 
2) the last visit before patient discontinued the study, or 3) April 2003, whichever comes 
first. Data were assumed missing completely at random (MCAR); thus we deleted 
observations where either the viral load or CD4 count was missing. Patients with only one 
observation were excluded. After exclusions, there were 1591 patients from the Aquitaine 
cohort and 1726 patients from the SHCS (see Web-Supplementary Material B1 for a 
description of patient selection). Table 3 gives descriptive statistics. For most patients, 
follow up ended with administrative censoring and therefore we assumed censoring was not 
informative.
Table 4 displays the results we obtained for the effect of treatment on CD4 counts. The naive 
Model 1, not corrected for treatment assignment, indicated a small and non-significant 
increase in CD4 for SHCS cohort, and a significant negative effect for the Aquitaine Cohort; 
thus illustrating the need for modeling treatment assignment. This is corrected by the use of 
a treatment model in MSM Models 2. Models 3 and 4 led to similar results in the SHCS and 
different results in the Aquitaine cohort. For Model 4, this may be because covariates other 
than CD4 count are also confounders (such as viral load). For Model 3, some covariates 
driving the choice of treatment initiation may have been omitted in the treatment model. 
Estimates from both Models 3 and 4 suggest that treatment causes a significant increase in 
CD4 within the first year and in subsequent years. The one-year increase, however, was 
much smaller for the Aquitaine cohort than for the SCHS when using MSM-based models. 
See Web-Supplementary Material B2 for a discussion of this result in relation with a 
possible practical violations of the experimental treatment assumption Cole and Hernán 
(2008). The results of the dynamical models, especially Models 6 and 7, were more 
consistent between cohorts.
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Model 6 is interesting because it dissociates the effect of the treatment on CD4 count from 
its effects on viral load. In this model, the estimated treatment effect on CD4 count was 
small in both cohorts and was non-significant for the Aquitaine cohort. In contrast, the effect 
on viral load was highly significant in both cohorts. This is consistent with the mode of 
action of antiretroviral treatment: the increase in CD4 count is essentially mediated by the 
decrease in viral load; the latter is the direct effect of treatment. Such biological knowledge 
is incorporated in Model 7, where the treatment acts on the infectivity parameter. In view of 
the Z-statistics obtained by a Wald test of the hypothesis β = 0 in Equation 2.9, the statistical 
evidence obtained in Model 7 is very high (this is confirmed by a likelihood ratio test). 
Moreover, Model 7 gives an insight into the value of the biological birth and death rates of 
cells during the infection (see Web-Supplementary Material B3). Regarding these biological 
parameters, the estimates from the two data sets are rather consistent in the sense that they 
have the same order of magnitude, although a formal comparison would show that several 
parameters are different, potentially due to different characteristics of the patients in the two 
cohorts. Finally, a simple way to look at these results and to compare them, is to consider the 
mean evolution in CD4 over time. Figure 2 represents the predicted CD4 counts with 
Models 1 to 7 for treated patients starting at baseline with CD4 count of 365 and a viral load 
of 4.4 (which are approximately the mean values at treatment initiation in these cohorts). For 
Models 1-3, these curves are deterministic, which is not the case for Models 4-7 because 
these models have random effects. For these latter models, we computed the mean predicted 
curves depending on the value of the random effect, which have to be set to values 
compatible with the baseline values of the biomarkers. In order to set them, in both cases, 
we computed the equilibrium point of the system without treatment and solved the system of 
equations. Figure 2 shows that the naive Model 1 is not in agreement with medical 
knowledge. Models 1-3 are unstable, whereas Models 4-7 are more consistent between the 
two studies. Models 3, 4 and 5 lead to similar trajectories in the SHCS dataset but very 
different trajectories in the Aquitaine Cohort study. In the latter, because trajectories for 
Model 3 look unrealistic and too pessimistic, we believe LIM Models 4 or 5 is more 
realistic. This illustrates the instability of weighted approaches. Finally, Model 5, 6 and 7 
have an equilibrium point. Model 7 reaches a steady state in about 1 year which is in line 
with observed data and is similar in both cohorts.
5. Conclusion
In this paper we estimated the effect of HAART on CD4 count using four dynamic models 
and compared estimates with those from a naive regression model, a variant of a previously 
proposed MSM and a MSM based on linear increments. This is an empirical comparison 
rather than a theoretical comparison. We discussed assumptions and validity of the various 
approaches together with possible bias in estimates, statistical evidence and practicability of 
use. The naive regression model (Model 1) strongly underestimated the effect of the 
treatment. The MSMs (Models 2 and 3) corrected this misleading result but sometimes 
failed to reach significance or were unstable across cohorts. The discrete-time dynamic 
models (Models 4, 5 and 6) based on LIM gave rather good estimates and show higher 
statistical evidence, although they may sometimes be too rigid. All the discrete-time models 
are easily fit without specialist software. The continuous-time dynamic model based on 
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ODE-NLME (Model 7) gave good results. Models 6 and 7, which jointly model CD4 and 
viral load gave the most consistent results, with a richer interpretation since they explicitly 
model the effect of HAART on CD4 via a direct effect on viral load.
We have used a linear MSM with two slopes similar to that proposed by Cole et al. (2005). 
This model adequately represents the short term (few years) effect of treatment but not the 
long-term effect because the effect in subsequent years implies a biologically implausible 
indefinite increase over time. As pointed out by the Associate Editor, because MSM can 
specify any reasonable outcome regression model, ranging from a very simple model which 
posits that only the most recent exposures affect the outcome to something very complex - 
e.g. a spline-weighted sequence of exposures (Xiao et al., 2014), it would be possible to 
define an MSM in which the effect would be bounded. However, this would be at the cost of 
additional non-linear parametrization. Also, it would be possible to use more recent methods 
such as the history adjusted MSM (Petersen et al., 2007); these are most suited for dynamic 
treatment regimes whereas we assessed the effect of a static treatment regimes in this work. 
In contrast most dynamical models (although not Model 4) have an equilibrium point. We 
showed that a MSM could be fitted for the increment  rather than for . Thus, the MSM 
approach could complement the dynamic approach in the sense that less stringent 
assumptions would be needed for causal inference. However, the dynamic models already do 
a good job and the need to correct them (at the price of more complex procedure and loss of 
statistical evidence) is not obvious. In this paper we assumed MCAR observations for GEE, 
which is appropriate because most patients were administratively censored. MAR 
observations can be treated by using inverse probability of censorship weights (see Web-
Supplementary Material Section B4). One advantage of likelihood-based dynamic models is 
that they are still valid given MAR observations.
The mechanistic Model 7 directly incorporates biological knowledge. This leads to a more 
significant test for the parameter of interest. The simulated data in the paper are obtained 
with a dynamic model, so one might think that this favors dynamic models; however the true 
generation process comes itself from a complex dynamic system. Thus, the simulated model 
is much more complex than Models 4-7 which are highly misspecified. Of course, 
misspecification is not only a binary feature but can be quantified, in principle, for instance 
by the Kullback-Leibler risk between the generating distribution and the best distribution in 
the model (Commenges, 2015). Both simulated and real data are more complex than the 
models used to analyse that data: in both cases, we know that the model is misspecified but 
we hope that the structure of the model captures essential features of the dynamics of the 
system. The comparison between dynamic and MSM approach remains empirical: we 
compare estimates from plausible MSM and dynamic models. Finally, mechanistic models, 
once estimated, open the possibility of designing optimal control of the therapy, as has been 
proposed on simulations by Adams et al. (2004); Ernst et al. (2006), and also Prague et al. 
(2012). The issue of “optimal treatment regime” has also been tackled outside of the context 
of mechanistic models (Petersen et al., 2007; Orellana et al., 2010; Saarela et al., 2015). The 
drawback of the continuous-time approach is that it is numerically challenging and requires 
special software running on cluster computers.
PRAGUE et al. Page 11
Biometrics. Author manuscript; available in PMC 2017 March 24.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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APPENDIX: Correspondence between parameters of Model 2, 3 and 4
The question of how parameters from a MSM and a dynamical model relate is difficult for 
two reasons: the models are constructed differently; the philosophical approach to causality 
is different. We will make this exercise for comparing the MSM Model 2 and the LIM 
Model 4. One can reconcile the two philosophical approaches by saying that the “causal” 
interpretation (in a interventional point of view) is that for a given treatment trajectory , 
we expect under the MSM: 
. Model 4 is 
formulated in terms of the increments: , which by 
summation gives , where 
 is a martingale. This is the Doob decomposition of the process Y. With the 
assumption of a “perfect” system or a NUC system (see Commenges and Gégout-Petit 
(2015) and Chapter 9 of Commenges and Jacqmin-Gadda (2015)), if we apply treatment 
trajectory , this define a new probability P a under which the Doob decomposition, which 
is: , from which we deduce: 
. Thus, Model 4 yields the same 
expectation under an intervention imposing treatment trajectory  as Models 2 if β4 = 1, 
and the parameters giving the effects of  and  correspond. The same 
correspondence holds for Model 3, which is equivalent to Model 2 if the observations are 
equally spaced. Whereas Models 2 and 3 make the assumption that all confounders between 
A and Z are included in the computation of the inverse probability of treatment, Model 4 
assumes that there is no confounder between A and Z. For instance the viral load Vt−1 might 
be a confounder which is taken into account in inverse probability of treatment in Models 2 
and 3; in the dynamic approach one must use more complex models describing the dynamics 
of the viral load (such as Models 5 and 6). For Models 5, 6 and 7, marginal effects can still 
be computed (analytically or by simulation), but this may lead to complex forms, while 
generally MSM assume simple mathematical structures.
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Figure 1. 
Mechanistic models for HIV dynamics. Type of cells of interest are viruses (V), effector 
cells E and CD4 cells which may be quiescent (Q), target cells (T, T1, T2) or infected (T*,
, ). Parameters are defined in Table 1.
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Figure 2. 
Mean evolution in CD4 predicted by Model 1 (plain line, simple regression), Model 2 
(dashed line, MSM on ), Model 3 (dotted line, MSM on ), Model 4 (dotted line, simple 
LIM), Model 5 (dotted line, autoregressive LIM), Model 6 (dashed-dotted line, LIM 
system), and Model 7 (long-dashed line, mechanistic model) for treated patients starting 
with 365 CD4 cells/mL and a viral load of 4.4 log10 copies/mm3: (left) estimates from the 
SHCS data (right) estimates from the Aquitaine cohort. This figure appears in color in the 
electronic version of this article.
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Table 1
Meaning of parameters in the dynamical models presented in Figure 1. The upper part gives prior means and 
standard deviations for normal a priori distributions used for estimation of mechanistic parameters in Model 7 
for the ‘Target cell model’. The lower part gives parameter values used for data simulation from the Adams et 
al. (2005) model.
Normal priors used for analysis*
on the log value of the parameter
Name Description mean sd.
λ Natural production rate cellsμL . day 2.55 1.90
μ T* Natural death rate of T* cells
1
day −0.05 0.68
μ Q Natural death rate of Q cells 1day −9.00 1.00
α Transition rates between Q and T cells 1day −4.00 2.00
ρ Transition rates between T and Q cells 1day −4.34 1.38
μ T Virions natural death rate
1
day −2.59 0.34
γ Infectivity parameter μLday −5.76 4.02
π Rate of production of virions by infected cells 1day 4.04 2.66
μ V Natural death rate of T* cells
1
day 2.83 0.68
Parameter Value used for simulations
for each population (X)†
Name Description Units Type 1 Type 2 Effectors Virus
λ X Natural production rate cellsmL . day 5000 31.98 1.0 -
(1-ϵX) Treatment efficacy no unit 50% 83% - -
dX Natural death rate
1
day 0.01 0.01 0.25 -
δ X Infection-induced death rate 1day 0.7 0.7 0.1 -
ρ X Number of virions infecting a cell virionscells 1 1 - -
mX Immune-induced clearance rate
mL
cells.day 1 × 10
−5 1 × 10−5 - -
kX Infection rate
mL
virions.day 8 × 10
−7 1 × 10−4 - -
c Virions natural death rate
1
day - - - 13
NT Virions production per infected cells
virions
cells - - - 100
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Parameter Value used for simulations
for each population (X)†
Name Description Units Type 1 Type 2 Effectors Virus
Kb Saturation constant cells birth
cells
mL - - 100 -
Kd Saturation constant cells death
cells
mL - - 500 -
bE Infection-induced birth rate for E cells
1
day - - 0.3 -
*
Reference and explanation for these choices can be found in Prague et al. (2012).
†
For each simulated patient, every parameter got a random effect leading to 50% coefficient of variation
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Table 2
Estimated treatment effect on CD4 counts from simulated data: Model 1: Naive regression; Model 2: MSM on 
; Model 3: MSM on ; Model 4: Simple LIM; Model 5: autoregressive LIM; Model 6: LIM system; Model 
7: mechanistic model.
Simulated Dataset with Adams et al. (2005) model
n=200 n=1500
Model β treatment‡ Effect Sd. Z-stat† Effect Sd. Z-stat†
Model 1 < 1 yr 136 29 4.68 172 11 16.34
> 1 yr −11 6 −1.99 −12 2 −5.07
∞ − ∞ - - − ∞ - -
Model 2 < 1 yr 327 31 10.64 325 11 28.81
> 1 yr −14 10 −1.45 −7 4 −1.56
∞ − ∞ - - − ∞ - -
Model 3 < 1 yr 371 24 15.47 364 10 35.49
> 1 yr 8 3 2.45 4 1 3.2
∞ +∞ - - +∞ - -
Model 4 < 1 yr 362 17 21.60 378 6 61.35
> 1 yr 8 12 0.7 7 4 1.61
∞ +∞ - - +∞ - -
Model 5 < 1 yr 133 * * 136 * *
> 1 yr 84 * * 86 * *
∞ 359 * * 370 * *
β 1 149 5 31.24 154 2 89.36
Model 6 < 1 yr 325 * * 334 * *
> 1 yr 31 * * 34 * *
∞ CD4 360 * * 371 * *
∞ VL −1.9 * * −2 * *
β 1 600 21 28.42 630 8 82.22
α 1 −6.6 0.16 −40.86 −6.9 0.06 −120.51
Model 7 < 1 yr 312 * * 304 * *
> 1 yr 2 * * 4 * *
∞ CD4 308 * * 306 * *
∞ VL −5.6 * * −4.98 * *
β −1.12 0.014 −79.3 −1.03 0.003 −295.6
†
Estimates for treatment effect (β) are significant at level 10% if the absolute value of Z-stat is greater than 1.64 and significant at level 5% if the 
absolute value of Z-stat is greater than 1.96.
‡
To be compared with mean treatment effect in treated for (< 1 year; > 1 year; ∞): benchmarks values are (350;12;370) for these simulations.
*Simulated delta-method can lead to estimation of these values, but is not implemented here. Indeed, for Model 5, 6 and 7 significance of the 
treatment effect has to be evaluated through the mechanistic parameters β1,α1 and β.
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Table 3
Data description for illustrations : Average viral load, CD4 counts and percentage of treatment assignment in 
the population are displayed for simulated data and real data from the Aquitaine cohort and the SHCS. 
Statistics displayed are mean [Q1;Q3].
Simulated
dataset
Aquitaine
Cohort SHCS
n 200 1500 1591 1726
Missing data
Administrative - - 81.6% 74.7%
Death - - 12.7% 6.4%
Lost of follow-up - - 5.7% 18.9%
CD4 count
Baseline 428 [ 266 ; 545 ] 420 [ 253 ; 530 ] 471 [ 298 ; 612 ] 536 [ 357 ; 670 ]
Follow-up untreated 594 [ 485 ; 675 ] 588 [ 478 ; 656 ] 625 [ 440 ; 762 ] 543 [ 363 ; 675 ]
Follow-up treated 627 [ 417 ; 837] 606 [ 405 ; 801 ] 492 [ 315 ; 638 ] 507 [ 300 ; 660 ]
Viral Load
Baseline 3.9 [ 3.3 ; 4.6 ] 4 [ 3.4 ; 4.7 ] 4.2 [ 3.6 ; 4.8 ] 4.0 [ 3.4 ; 4.6 ]
Follow-up untreated 3.5 [ 2.9 ; 4.2 ] 3.7 [ 3.1 ; 4.4 ] 3.3 [ 2.3 ; 4.2 ] 3.8 [ 3.1 ; 4.5 ]
Follow-up treated 2.6 [ 1.7 ; 3.2 ] 2.6 [ 1.7 ; 3.2 ] 2.7 [ 1.7 ; 3.6 ] 3.2 [ 2.4 ; 4.1 ]
% undetectable viral load
(baseline,untreated, treated)
(3%;4%;40%) (2%;3%;38%) (7%;22%;48%) (10%;15%;57%)
Treatment assignment
Time (day) 412 [ 1 ; 631 ] 377 [ 91 ; 451 ] 727 [ 1 ; 1281 ] 548 [ 183 ; 752 ]
% treated 69% 65% 64% 34%
Biometrics. Author manuscript; available in PMC 2017 March 24.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
PRAGUE et al. Page 21
Table 4
Estimated treatment effect on CD4 counts from real data of the Aquitaine cohort and SHCS: Model 1: Naive 
regression; Model 2: MSM on ; Model 3: MSM on ; Model 4: Simple LIM; Model 5: autoregressive LIM; 
Model 6: LIM system; Model 7: mechanistic model.
Real Dataset observational studies
SHCS Aquitaine Cohort
Model β treatment Effect Sd. Z-stat† Effect Sd. Z-stat†
Model 1 < 1 yr 6 16 0.34 −94 12 −7.55
> 1 yr 30 6 5.42 30 3 9.75
∞ +∞ - - +∞ - -
Model 2 < 1 yr 208 18 11.31 36 19 1.87
> 1 yr 50 9 5.79 53 5 9.62
∞ +∞ - - +∞ - -
Model 3 < 1 yr 174 10 17.29 27 14 1.99
> 1 yr 61 5 12.37 34 5 6.3
∞ +∞ - - +∞ - -
Model 4 < 1 yr 189 11 17.33 109 9 12.03
> 1 yr 73 8 9.07 55 6 8.99
∞ +∞ - - +∞ - -
Model 5 < 1 yr 26 * * 45 * *
> 1 yr 14 * * 19 * *
∞ 55 * * 79 * *
β 1 60 4 16.04 14 3 4.12
Model 6 < 1 yr 73 * * 92 * *
> 1 yr 26 * * 16 * *
∞ CD4 104 * * 111 * *
∞ VL −2.0 * * −2.3 * *
β 1 80 16 5 28 18 1.53
α 1 −3.29 0.09 −38.4 −3.19 0.1 −30.55
Model 7 < 1 yr 104 * * 71 * *
> 1 yr 18 * * 9 * *
∞ CD4 127 * * 86 * *
∞ VL −4.09 * * −3.14 * *
β −1.73 0.05 −34.79 −0.89 0.01 −85.77
†
Estimates for treatment effect (β) are significant at level 10% if the Z-stat is greater than 1.64 and significant at level 5% if the Z-stat is greater 
than 1.96.
*Simulated delta-method can lead to estimation of these values, but is not implemented here. Indeed, for Model 5, 6 and 7 significance of the 
treatment effect has to be evaluated through the mechanistic parameters β1,α1 and β.
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